Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors
- 1 May 2015
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 96, 196-208
Abstract
No abstract availableKeywords
Funding Information
- NIH (CA107568)
This publication has 23 references indexed in Scilit:
- A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemiaEMBO Molecular Medicine, 2013
- Molecular Basis of Triple Negative Breast Cancer and Implications for TherapyInternational Journal of Breast Cancer, 2011
- Triple-Negative Breast Cancer: An Unmet Medical NeedThe Oncologist, 2011
- Stereoselective Synthesis of Chiral IBR2 AnaloguesThe Journal of Organic Chemistry, 2009
- The consequences of Rad51 overexpression for normal and tumor cellsDNA Repair, 2008
- Asymmetric Friedel−Crafts Reaction of Indoles with Imines by an Organic CatalystJournal of the American Chemical Society, 2006
- Rad51 overexpression promotes alternative double-strand break repair pathways and genome instabilityOncogene, 2004
- Insights into DNA recombination from the structure of a RAD51–BRCA2 complexNature, 2002
- Effects of HsRad51 Overexpression on Cell Proliferation, Cell Cycle Progression, and ApoptosisExperimental Cell Research, 2001
- A Novel Synthesis of 3-Substituted Indazole DerivativesSynthesis, 1992